Alectinib

Alectinib is a tyrosine kinase receptor inhibitor that can inhibit anaplastic lymphoma kinase (ALK) and RET.
Abnormal ALK gene expression brought on by using mutations or translocations can lead to the expression of oncogenic fusion proteins (such as ALK fusion proteins), which alter sign transduction and expression, and lead to extended proliferation and survival of tumor cells expressing these fusion proteins. The inhibition of ALK phosphorylation and ALK mediated activation of downstream signaling lead to a minimize in tumor mobile viability. Aletinib has a greater impact on ALK than clotozantinib and can inhibit most of the obtained ALK resistance mutations found in scientific practice.